Genethon Expects to Begin Phase 3 Trials of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy in 2025 in Europe, Followed by US

Genethon Expects to Begin Phase 3 Trials of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy in 2025 in Europe, Followed by US

#dmd #duchenne #bmd #becker
#genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #gene #dna #genethon #gnt0004 #europe #2025

GNT004 Duchenne Muscular Dystrophy

Genethon’s CEO, Frederic Revah discusses how the drug candidate GNT004 has the potential of becoming best-in-class gene therapy for DMD (Duchenne Muscular Dystrophy).

Source: www.youtube.com/watch?v=YtTX...

#dmd #bmd #hope #science
#genetherapy #dmdwarrior #dmdwarriors #genethon #gnt0004

Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago

Source: bit.ly/3ZiNRdp

#genethon #gnt0004 #dmd #duchenne #dmdwarrior #genetherapy